22.68

1.11% 0.25

Pre-market: 22.31 -0.37 -1.63%

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Why RCUS Down? Discussions Forecast

Arcus Biosciences Inc stock is traded at $22.68, with a volume of 1.02M. It is up +1.11% in the last 24 hours and up +8.05% over the past month. Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Previous Close:

$22.43

Open:

$22.67

24h Volume:

1.02M

Relative Volume:

0.66

Market Cap:

$2.81B

Revenue:

$247.00M

Net Income/Loss:

$-249.00M

P/E Ratio:

-7.3398

EPS:

-3.09

Net Cash Flow:

$-267.00M

1W Performance:

+11.89%

1M Performance:

+8.05%

6M Performance:

+96.19%

1Y Performance:

+134.06%

1-Day Range:

$21.80

$22.77

1-Week Range:

$19.21

$24.74

52-Week Range:

$6.50

$26.40

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

(510) 694-6200

Address

3928 POINT EDEN WAY, HAYWARD, CA

Employee

674

Twitter

@arcusbio

Next Earnings Date

2024-12-06

Latest SEC Filings

RCUS's Discussions on Twitter

Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCUS Arcus Biosciences Inc	22.68	2.78B	247.00M	-249.00M	-267.00M	-3.09
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-26	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-13-26	Upgrade	Goldman	Neutral → Buy
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-21-24	Initiated	H.C. Wainwright	Neutral
Oct-08-24	Initiated	Wells Fargo	Overweight
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

04:25 AM

Fisher Asset Management LLC Acquires 640,990 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat

04:25 AM

Mar 04, 2026

RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 04, 2026

Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com

Mar 04, 2026

Mar 03, 2026

Risk Analysis: Is Arcus Biosciences Inc still a buy after recent gainsWeekly Earnings Recap & Weekly Sector Rotation Insights - baoquankhu1.vn

Mar 03, 2026

RCUS Stock Jumps 17.5% Despite $353M Net Loss: What $34 Fair Value Signals - TIKR.com

Mar 03, 2026

Arcus Biosciences (RCUS) Is Up 27.0% After Casdatifan Kidney Cancer Data And TKI-Free Strategy Shift - simplywall.st

Mar 03, 2026

The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts - Sahm

Mar 03, 2026

Arcus Biosciences: Q4 Beat And Casdatifan’s Story So Far (NYSE:RCUS) - Seeking Alpha

Mar 03, 2026

Mar 02, 2026

RCUS Analyst Rating Updated by Leerink Partners | RCUS Stock New - GuruFocus

Mar 02, 2026

Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat

Mar 02, 2026

Arcus Biosciences (NYSE:RCUS) Shares Up 9.5%Here's What Happened - MarketBeat

Mar 02, 2026

Arcus Biosciences (NYSE:RCUS) Given "Buy" Rating at HC Wainwright - MarketBeat

Mar 02, 2026

Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage - Yahoo Finance

Mar 02, 2026

Arcus Biosciences (RCUS) Analyst Rating Reaffirmed with Target P - GuruFocus

Mar 02, 2026

HC Wainwright Brokers Increase Earnings Estimates for RCUS - MarketBeat

Mar 02, 2026

Mar 01, 2026

Performance Recap: Is Arcus Biosciences Inc stock a buy or sellEarnings Miss & Community Consensus Trade Alerts - baoquankhu1.vn

Mar 01, 2026

Can Arcus Biosciences Inc stock double in the next year2025 Growth vs Value & Accurate Technical Buy Alerts - baoquankhu1.vn

Mar 01, 2026

Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Rebound And Casdatifan Expectations - simplywall.st

Mar 01, 2026

Feb 28, 2026

Arcus Biosciences Q4 Earnings Call Highlights - Yahoo Finance

Feb 28, 2026

Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives - Sahm

Feb 28, 2026

Feb 27, 2026

Arcus Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:RCUS) 2026-02-27 - Seeking Alpha

Feb 27, 2026

Arcus Biosciences (RCUS) Stock Analysis: Is A 65% Upside In Reach? - DirectorsTalk Interviews

Feb 27, 2026

Cancer and immune drug developer Arcus Biosciences offers March webcast - Stock Titan

Feb 26, 2026

Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st

Feb 26, 2026

Arcus Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 26, 2026